Reading Time: 1 minute
I believe we will see disruptive developments in healthcare in terms of many clinical phase startups for the development of new drugs. AI accelerates the identification and evaluation of new active ingredients. This leads to a higher number of molecules entering clinical phases. An additional boost could occur in the next decade with the introduction of quantum computers. Quantum computers can calculate highly complex interactions. Furthermore, quantum computers are expected to especially assist in the early stages of drug development when it comes...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.

